

## IN THE CLAIMS

Please amend the claims as indicated below. The following listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-21 (cancelled)

Claim 22 (currently amended): An isolated *Listeria monocytogenes* bacterium which comprises; is

(a) a deletion in the genomic *actA* and *inlB* genes of the bacterium whereby the bacterium does not express ActA or InlB proteins; defective with respect to internalin B, such that the bacterium is attenuated for entry into non-phagocytic cells relative to wild type, and

(b) a functional genomic *inlA* gene whereby the bacterium expresses InlA protein; and defective with respect to ActA, such that the bacterium is attenuated for cell to cell spread relative to wild type;

wherein the non-phagocytic cells are hepatocytes

(c) a nucleic acid sequence encoding a non-*Listerial* polypeptide operably linked to a promoter sequence directing expression of the polypeptide whereby the bacterium expresses the non-*Listerial* polypeptide.

Claims 23-37 (cancelled)

Claim 38 (currently amended): A composition comprising (a) the attenuated *Listeria* bacterium of claim 22, and (b) an adjuvant.

Claim 39 (currently amended): A method of inducing an immune response in a host to ~~an~~ a non-*Listerial* antigen comprising administering to the host an effective amount of a composition comprising the attenuated *Listeria* bacterium of claim 22, wherein the attenuated *Listeria* bacterium comprises a nucleic acid non-*Listerial* polypeptide comprises encoding the non-*Listerial* antigen.

Claim 40 (currently amended): A method of ~~treating a disease~~ expressing a non-*Listerial* polypeptide in a host, comprising administering to the host an effective amount of a composition comprising the ~~attenuated~~ *Listeria* bacterium of claim 22 expressing the non-*Listerial* polypeptide.

Claim 41 (currently amended): An isolated professional antigen-presenting cell comprising the ~~attenuated~~ *Listeria* bacterium of claim 22.

Claims 42-75 (cancelled)

Claim 76 (currently amended): The method of claim 40, wherein the ~~disease~~ host is selected on the basis of a diagnosis of cancer in the host.

Claim 77 (currently amended). ~~A~~ The method of claim 40, wherein the host is selected on the basis of a need for providing protection against a disease in a the host, ~~comprising administering to the host an effective amount of a composition comprising the attenuated~~ *Listeria* bacterium of claim 22.

Claims 78-80 (cancelled)

Claim 81 (previously presented): The method of claim 77, wherein the disease is an infectious disease.

Claim 82 (previously presented): The method of claim 77, wherein the disease is cancer.

Claim 83 (currently amended): A pharmaceutical composition comprising (a) the ~~attenuated~~ *Listeria* bacterium of claim 22, and (b) a pharmaceutically acceptable carrier.

Claims 84-89 (cancelled)

Claim 90 (currently amended): The method of claim 40, wherein the ~~disease~~ host is selected on the basis of a diagnosis of an infectious disease in the host.

Claims 91-110 (cancelled)